(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 5.1% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 7.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.83%.
10x Genomics's revenue in 2026 is $638,783,000.On average, 16 Wall Street analysts forecast TXG's revenue for 2026 to be $78,711,567,618, with the lowest TXG revenue forecast at $75,328,185,181, and the highest TXG revenue forecast at $83,075,051,834. On average, 16 Wall Street analysts forecast TXG's revenue for 2027 to be $85,823,653,326, with the lowest TXG revenue forecast at $79,814,816,901, and the highest TXG revenue forecast at $92,557,409,590.
In 2028, TXG is forecast to generate $94,421,126,445 in revenue, with the lowest revenue forecast at $85,064,455,316 and the highest revenue forecast at $106,243,286,765.